Related takeovers provide clinical trial management and regulatory services throughout China.
WuXi Pharmaceuticals has bought two related Shanghai-based contract clinical research development services, MedKey Med-Tech Development and Jiecheng Med-Tech Development. Founded in 2006, the two acquired firms provide services spanning regulatory affairs, Phase I–IV clinical trials management, and clinical trial site management, throughout most of China.
“This acquisition provides WuXi an existing clinical development service capability and infrastructure that WuXi will expand and strengthen to serve our customers’ growing clinical development needs in the fast-growing Chinese healthcare market,” comments Ge Li, Ph.D., chairman and CEO.
WuXi is a pharma, biotech, and medical device R&D outsourcing specialist with operations in China and the U.S. Just 10 days ago it reported acquiring antibody and peptide reagents firm Abgent, including the latter’s facilities in China and San Diego.
